A detailed history of Manufacturers Life Insurance Company, The transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 22,057 shares of ITCI stock, worth $1.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,057
Previous 21,774 1.3%
Holding current value
$1.88 Million
Previous $1.49 Million 8.12%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$67.99 - $80.84 $19,241 - $22,877
283 Added 1.3%
22,057 $1.61 Million
Q2 2024

Aug 14, 2024

SELL
$64.76 - $79.84 $2.02 Million - $2.5 Million
-31,267 Reduced 58.95%
21,774 $1.49 Million
Q1 2024

May 14, 2024

SELL
$64.37 - $75.65 $1.72 Million - $2.02 Million
-26,701 Reduced 33.48%
53,041 $3.67 Million
Q4 2023

Feb 13, 2024

BUY
$46.37 - $73.65 $1.21 Million - $1.92 Million
26,108 Added 48.68%
79,742 $5.71 Million
Q3 2023

Nov 15, 2023

BUY
$52.09 - $64.1 $820,573 - $1.01 Million
15,753 Added 41.59%
53,634 $2.79 Million
Q2 2023

Aug 11, 2023

BUY
$54.67 - $66.44 $59,316 - $72,087
1,085 Added 2.95%
37,881 $2.4 Million
Q1 2023

May 15, 2023

BUY
$43.8 - $56.99 $5,825 - $7,579
133 Added 0.36%
36,929 $2 Million
Q4 2022

Aug 11, 2023

BUY
$44.07 - $54.45 $33,184 - $41,000
753 Added 2.09%
36,796 $1.95 Million
Q4 2022

Feb 13, 2023

BUY
$44.07 - $54.45 $33,184 - $41,000
753 Added 2.09%
36,796 $1.95 Million
Q3 2022

Aug 11, 2023

SELL
$42.7 - $59.99 $26,089 - $36,653
-611 Reduced 1.67%
36,043 $1.68 Million
Q3 2022

Nov 03, 2022

SELL
$42.7 - $59.99 $26,089 - $36,653
-611 Reduced 1.67%
36,043 $1.68 Million
Q2 2022

Aug 11, 2023

BUY
$43.0 - $65.64 $171,312 - $261,509
3,984 Added 12.19%
36,654 $2.09 Million
Q2 2022

Aug 15, 2022

BUY
$43.0 - $65.64 $171,312 - $261,509
3,984 Added 12.19%
36,654 $2.09 Million
Q1 2022

Aug 11, 2023

SELL
$38.74 - $62.09 $164,993 - $264,441
-4,259 Reduced 11.53%
32,670 $2 Million
Q1 2022

May 20, 2022

SELL
$38.74 - $62.09 $67,756 - $108,595
-1,749 Reduced 5.08%
32,670 $2 Million
Q4 2021

Feb 16, 2022

SELL
$35.2 - $53.42 $14,819 - $22,489
-421 Reduced 1.21%
34,419 $1.8 Million
Q3 2021

Nov 12, 2021

SELL
$28.72 - $42.49 $99,715 - $147,525
-3,472 Reduced 9.06%
34,840 $1.3 Million
Q2 2021

Aug 12, 2021

BUY
$29.3 - $44.5 $68,034 - $103,329
2,322 Added 6.45%
38,312 $1.56 Million
Q1 2021

May 03, 2021

SELL
$30.8 - $39.51 $75,213 - $96,483
-2,442 Reduced 6.35%
35,990 $1.22 Million
Q4 2020

Feb 12, 2021

BUY
$23.34 - $32.22 $54,008 - $74,557
2,314 Added 6.41%
38,432 $1.22 Million
Q3 2020

Nov 09, 2020

BUY
$17.61 - $31.86 $78,804 - $142,573
4,475 Added 14.14%
36,118 $927,000
Q2 2020

Aug 10, 2020

BUY
$14.35 - $26.64 $4,104 - $7,619
286 Added 0.91%
31,643 $797,000
Q1 2020

May 15, 2020

BUY
$12.31 - $33.12 $64,122 - $172,522
5,209 Added 19.92%
31,357 $482,000
Q4 2019

Feb 14, 2020

SELL
$7.26 - $38.49 $10,672 - $56,580
-1,470 Reduced 5.32%
26,148 $897,000
Q2 2019

Aug 14, 2019

SELL
$10.65 - $14.29 $13,568 - $18,205
-1,274 Reduced 4.41%
27,618 $358,000
Q1 2019

May 13, 2019

BUY
$10.9 - $14.09 $11,793 - $15,245
1,082 Added 3.89%
28,892 $352,000
Q4 2018

Feb 14, 2019

SELL
$10.36 - $20.96 $7,148 - $14,462
-690 Reduced 2.42%
27,810 $317,000
Q3 2018

Nov 14, 2018

SELL
$17.77 - $22.9 $69,054 - $88,989
-3,886 Reduced 12.0%
28,500 $619,000
Q2 2018

Aug 14, 2018

BUY
$17.33 - $23.4 $32,719 - $44,179
1,888 Added 6.19%
32,386 $572,000
Q1 2018

May 15, 2018

SELL
$15.16 - $25.49 $17,009 - $28,599
-1,122 Reduced 3.55%
30,498 $642,000
Q4 2017

Feb 08, 2018

BUY
$14.27 - $16.79 $89,529 - $105,340
6,274 Added 24.75%
31,620 $458,000
Q3 2017

Nov 14, 2017

BUY
$10.77 - $22.1 $272,976 - $560,146
25,346
25,346 $400,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.05B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.